Recent Finacing
Recent Raise
T3D Therapeutics is a clinical-stage biotech developing oral T3D-959, a brain‑penetrant dual nuclear receptor agonist that targets glucose and lipid metabolism dysfunctions in Alzheimer's and is in Phase 2 trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at T3D Therapeutics.
